



*Better Health, Brighter Future*

# Financial Results for 1<sup>st</sup> Half of FY2015 DATA BOOK

**Takeda Pharmaceutical Company Limited (TSE code 4502)**

**Contact: Global Finance, IR**

TEL: +81-3-3278-2306

<http://www.takeda.com/>

**Quarterly Announcements / Presentations**

<http://www.takeda.com/investor-information/results/>

---

## Contents


---

I. Overview of Takeda group	1
■ Number of subsidiaries and affiliates by business segment	
II. Financial Results	
1. Financial highlights	2
2. Consolidated Statements of Income	3
3. Revenue / Product Sales	4-6
◆ Revenue by Regions	
◆ Ethical Drugs Revenue	
◆ Major Subsidiaries	
◆ Ethical Drugs: Global major products' sales	
◆ Ethical Drugs: Overseas major products' sales (Regional basis)	
◆ Ethical Drugs: US major products' sales (in US\$)	
◆ Ethical Drugs: Japan major products' sales	
◆ Consumer Healthcare: Major products' sales	
4. Consolidated Statement of Financial Position	7-8
5. Consolidated Statement of Cash Flows	8
6. Segment Information	9
7. Capital expenditure, depreciation and amortization and impairment losses	9
8. Number of employees	10
9. Shareholders	11
10. Financial ratios	12
III. Pipeline	
1. Development Activities	13-17
■ US/EU/Japan	
■ Additional indications/formulations/important label updates of approved compounds	
■ Recent progress in stage	
■ Discontinued projects	
■ Filings and Approvals in Brazil, China and Russia	
■ Clinical study protocol summaries	
2. Research Activities	18
■ Main joint research activities	

---

# I. Overview of Takeda group

The Takeda Group consists of 152 companies, including the parent company submitting these consolidated financial statements, 135 consolidated subsidiaries and 16 affiliates accounted for by the equity method. The following chart shows the main business areas of the Takeda Group, the position of the companies that make up the Group within their respective areas of business, and relationships with each business segment.



## II. Financial Results

### 1. Financial highlights (more detail will be available in Page 3 and onward)

Consolidated operating results (Billion JPY)	FY12	FY13	FY14	FY15 Forecasts	FY14	FY15	vs. PrY	increase/ decrease
					H1	H1		
Revenue	1,557.0	1,691.7	1,777.8	1,820.0	851.4	904.0	52.7	6.2%
Overseas revenue	822.7	957.8	1,065.0	1,130.0	492.0	559.2	67.2	13.6%
<% of Revenue>	<52.8%>	<56.6%>	<59.9%>	<62.1%>	<57.8%>	<61.9%>	<4.1pt>	
Revenue of ethical drugs segment	1,401.5	1,529.1	1,614.5	1,670.0	770.1	825.5	55.4	7.2%
R&D expenses *1	321.3	341.6	351.2	330.0	140.9	161.4	20.5	14.5%
<% of Revenue>	<20.6%>	<20.2%>	<19.8%>	<18.1%>	<16.6%>	<17.9%>	<1.3pt>	
Operating profit	65.0	139.3	-129.3	105.0	116.7	110.4	-6.2	-5.4%
<% of Revenue>	<4.2%>	<8.2%>	<-7.3%>	<5.8%>	<13.7%>	<12.2%>	<-1.5pt>	
Profit before income taxes	133.1	158.9	-145.4	115.0	113.1	102.0	-11.1	-9.8%
<% of Revenue>	<8.5%>	<9.4%>	<-8.2%>	<6.3%>	<13.3%>	<11.3%>	<-2.0pt>	
Net profit for the year	150.7	109.6	-143.0		63.2	56.0	-7.2	-11.3%
<% of Revenue>	<9.7%>	<6.5%>	<-8.0%>		<7.4%>	<6.2%>	<-1.2pt>	
Profit attributable to owners of the Company	148.6	106.7	-145.8	68.0	61.4	54.4	-7.1	-11.5%
<% of Revenue>	<9.5%>	<6.3%>	<-8.2%>	<3.7%>	<7.2%>	<6.0%>	<-1.2pt>	
Core earnings *2	285.5	314.2	288.3		169.9	177.5	7.6	4.5%
<% of Revenue>	<18.3%>	<18.6%>	<16.2%>		<19.9%>	<19.6%>	<-0.3pt>	

\*1 Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed. For the purpose to compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.

\*2 Profit from regular business calculated by deducting any temporary factors such as impacts from business combination accounting and from amortization/impairment loss of intangible assets etc., from operating profit.

Consolidated financial position (Billion JPY)	FY12 End	FY13 End	FY14 End	FY14 H1 End	FY15 H1 End	vs. FY14 End
Total assets	4,052.6	4,569.1	4,296.2		4,213.8	-82.4
Total liabilities	1,714.3	2,028.5	2,090.0		2,031.5	-58.5
Total equity	2,338.3	2,540.6	2,206.2		2,182.3	-23.9
Equity attributable to owners of the Company	2,274.1	2,470.7	2,137.0		2,119.4	-17.6
Ratio of equity attributable to owners of the Company to total assets	56.1%	54.1%	49.7%		50.3%	0.6pt

Shares	FY12 End	FY13 End	FY14 End	FY14 H1 End	FY15 H1 End
Number of shares outstanding (1,000)	789,666	789,681	789,924	789,735	790,151
Treasury stock (1,000)	206	213	4,032	4,028	6,741
Stock price at year-end (JPY)	5,030	4,892	5,999	4,768	5,237
Total market value (Billion JPY)	3,972.0	3,863.1	4,738.8	3,765.5	4,138.0

ROE•EPS•Dividend (JPY)	FY12	FY13	FY14	FY14	FY15	vs. PrY
				H1	H1	
Return on equity attributable to owners of the Company	6.8%	4.5%	-6.3%	5.0%	5.1%	0.1%
Basic earnings per share	188.21	135.10	-185.37	78.07	69.34	-8.73
Annual dividends per share	180.00	180.00	180.00	90.00	90.00	-
Dividend pay-out ratio	95.6%	133.2%	-	115.3%	129.8%	14.5pt

Exchange rate(JPY)	FY12	FY13	FY14	FY15 Assumptions	FY14	FY15
					H1	H1
US\$ Average (Apr.-Mar.)	82	100	109	120	102	122
Euro Average (Apr.-Mar.)	106	133	139	135	139	134

## 2. Consolidated Statement of Income

	(Billions of Yen)				(Billions of Yen)			
	FY12	FY13	FY14	FY15 Forecasts	FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Revenue	1,557.0	1,691.7	1,777.8	1,820.0	851.4	904.0	52.7	6.2%
Royalty income	45.2	77.4	56.8		28.5	28.2	-0.4	-1.3%
Cost of sales *1	463.8	490.3	528.4		250.9	257.4	6.5	2.6%
<% of revenue>	<29.8%>	<29.0%>	<29.7%>		<29.5%>	<28.5%>	<-1.0pt>	
Gross Profit	1,093.2	1,201.4	1,249.4		600.5	646.6	46.2	7.7%
<% of revenue>	<70.2%>	<71.0%>	<70.3%>		<70.5%>	<71.5%>	<1.0pt>	
SG&A expenses *1	512.9	556.2	636.1		294.8	313.5	18.7	6.3%
<% of revenue>	<32.9%>	<32.9%>	<35.8%>		<34.6%>	<34.7%>	<0.0pt>	
Sales and Marketing expenses			436.1		201.0	225.4	24.5	12.2%
General Administrative expenses			200.0		93.9	88.1	-5.8	-6.2%
R&D expenses *1	321.3	341.6	351.2	330.0	140.9	161.4	20.5	14.5%
<% of revenue>	<20.6%>	<20.2%>	<19.8%>	<18.1%>	<16.6%>	<17.9%>	<1.3pt>	
Amortization and impairment losses on intangible assets associated with products	173.8	143.2	176.4		63.2	63.0	-0.3	-0.4%
Other operating income	24.1	23.9	107.2		38.7	15.2	-23.5	-60.7%
Government grant income	2.9	2.6	3.1		1.6	1.5	-0.1	-7.1%
Rental income	4.7	4.3	3.9		2.0	1.9	-0.0	-1.5%
Gains on sales of assets held for sale	4.1	6.6	32.8		25.4	0.0	-25.4	-100.0%
Royalty income on transfer of operations	4.3	4.7	6.5		6.4	4.9	-1.5	-22.8%
Others *2	8.1	5.6	60.8		3.4	6.9	3.5	101.9%
Other operating expenses	44.3	45.0	322.2		23.5	13.6	-9.9	-42.2%
Expenses directly attributable to rental income	2.3	5.0	2.2		1.2	1.2	-0.1	-7.3%
Donations and contributions	2.8	3.2	1.5		0.8	0.9	0.1	18.3%
Restructuring expenses *3	25.2	21.7	31.2		13.9	6.8	-7.1	-50.9%
Loss on Actos litigation	-	-	274.1		-	-	-	-
Others	13.9	15.1	13.2		7.6	4.7	-2.9	-38.0%
Operating profit	65.0	139.3	-129.3	105.0	116.7	110.4	-6.2	-5.4%
<% of revenue>	<4.2%>	<8.2%>	<-7.3%>	<5.8%>	<13.7%>	<12.2%>	<-1.5pt>	
Financial income	87.7	49.3	15.4		10.1	12.9	2.8	28.0%
Interest income	1.2	1.4	2.3		1.0	0.7	-0.2	-25.0%
Dividends income	4.0	3.3	3.3		1.6	1.7	0.2	10.0%
Gains on sales of available-for-sale financial assets	56.3	40.5	8.9		3.3	3.4	0.0	1.2%
Foreign exchange gains including gains on valuation of derivatives	11.1	4.1	-		3.9	6.8	2.9	73.1%
Interest on tax refund	15.1	-	-		-	-	-	-
Others	0.1	0.0	0.9		0.3	0.3	0.0	9.8%
Financial expenses	20.5	30.7	32.9		14.7	22.3	7.6	51.5%
Interest expenses	3.4	4.9	5.8		2.8	2.5	-0.3	-9.8%
Fair value adjustments of contingent considerations	6.5	11.0	16.2		8.1	4.5	-3.6	-44.1%
Impairment losses on available-for-sale financial assets	0.9	0.8	1.7		0.8	1.6	0.9	113.3%
Foreign exchange losses including losses on valuation of derivatives	6.7	11.8	3.9		-	12.4	12.4	-
Others	2.9	2.3	5.3		3.1	1.2	-1.9	-60.0%
Share of profit of associates accounted for using the equity method	0.9	1.0	1.3		1.1	1.0	-0.1	-9.2%
Profit before tax	133.1	158.9	-145.4	115.0	113.1	102.0	-11.1	-9.8%
Income tax expenses	-17.6	49.3	-2.4		50.0	46.1	-3.9	-7.9%
Net profit for the period	150.7	109.6	-143.0		63.2	56.0	-7.2	-11.3%
<% of revenue>	<9.7%>	<6.5%>	<-8.0%>		<7.4%>	<6.2%>	<-1.2pt>	
Attributable to Owners of the Company	148.6	106.7	-145.8	68.0	61.4	54.4	-7.1	-11.5%
<% of revenue>	<9.5%>	<6.3%>	<-8.2%>	<3.7%>	<7.2%>	<6.0%>	<-1.2pt>	
Total comprehensive income for the period	323.3	343.7	-180.9		78.0	68.4	-9.6	-12.3%
<% of revenue>	<20.8%>	<20.3%>	<-10.2%>		<9.2%>	<7.6%>	<-1.6pt>	
Attributable to Owners of the Company	318.8	339.2	-186.6		75.2	67.8	-7.5	-9.9%
<% of revenue>	<20.5%>	<20.0%>	<-10.5%>		<8.8%>	<7.5%>	<-1.3pt>	
Effective tax rate								
Japanese statutory tax rate	38.0%	38.0%	35.6%		35.6%	33.0%	-2.6pt	
Effective tax rate	-13.2%	31.0%	1.7%		44.2%	45.1%	1.0pt	

\*1 Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed.

For the purpose to compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.

\*2 Fair value adjustments of contingents considerations are included in "Others".

\*3 Expenses from reorganization, such as the consolidation of a number of sites and functions (including the potential merger or liquidation of subsidiaries) and the reduction of the workforce to build an efficient operating model.

### 3. Revenue / Product Sales

#### ◆ Revenue by Regions

				(Billion JPY)			
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Total revenue	1,557.0	1,691.7	1,777.8	851.4	904.0	52.7	6.2%
Japan	734.3	733.9	712.8	359.3	344.9	-14.5	-4.0%
Overseas	822.7	957.8	1,065.0	492.0	559.2	67.2	13.6%
<% of revenue>	<52.8%>	<56.6%>	<59.9%>	<57.8%>	<61.9%>	<4.1pt>	
United States	343.8	352.1	426.1	185.8	249.2	63.4	34.1%
<% of revenue>	<22.1%>	<20.8%>	<24.0%>	<21.8%>	<27.6%>	<5.7pt>	
Europe and Canada	263.2	320.0	325.3	156.6	157.1	0.5	0.3%
<% of revenue>	<16.9%>	<18.9%>	<18.3%>	<18.4%>	<17.4%>	<-1.0pt>	
Russia/CIS	68.3	89.6	81.3	38.0	32.1	-5.9	-15.5%
<% of revenue>	<4.4%>	<5.3%>	<4.6%>	<4.5%>	<3.6%>	<-0.9pt>	
Latin America	62.9	81.2	85.4	41.2	37.6	-3.5	-8.6%
<% of revenue>	<4.0%>	<4.8%>	<4.8%>	<4.8%>	<4.2%>	<-0.7pt>	
Asia	60.1	85.4	111.4	51.2	62.9	11.6	22.7%
<% of revenue>	<3.9%>	<5.0%>	<6.3%>	<6.0%>	<7.0%>	<0.9pt>	
Other	24.3	29.5	35.5	19.2	20.2	1.0	5.4%
<% of revenue>	<1.6%>	<1.7%>	<2.0%>	<2.3%>	<2.2%>	<-0.0pt>	
Royalty income	45.2	77.4	56.8	28.5	28.2	-0.4	-1.3%
Ethical drugs	44.8	77.3	56.6	28.5	28.1	-0.4	-1.4%
Japan	0.4	0.2	6.3	2.9	3.3	0.5	15.7%
Overseas	44.4	77.1	50.4	25.6	24.8	-0.9	-3.3%

\* Revenue amount is classified into countries or regions based on the customer location.

\*\* Effective from FY14, the Company changed the regional classification to ensure consistency with its global organizational structure (previous "North America" was divided into "United States" and "Canada", and "Canada" and previous "Europe" were integrated into "Europe and Canada"). For fair comparison purpose, the amounts reported in the periods of FY12 and FY13 were modified according to the new classification.

\*\*\* Other region includes Middle East, Oceania and Africa.

#### ◆ Ethical Drugs Revenue

				(Billion JPY)			
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Net Sales in Japan	586.9	580.0	553.2	279.4	268.4	-11.0	-3.9%
Net Sales Overseas	763.8	863.3	974.3	454.6	526.2	71.6	15.8%
United States	326.8	318.9	394.9	174.7	239.0	64.3	36.8%
Europe and Canada	228.0	265.6	287.1	139.2	142.8	3.6	2.6%
Russia/CIS	68.3	89.5	79.5	37.6	31.8	-5.8	-15.4%
Latin America	62.3	80.6	80.1	39.2	36.4	-2.8	-7.2%
Asia	55.5	80.5	102.4	47.0	57.9	10.9	23.3%
Other	22.9	28.1	30.3	16.8	18.2	1.4	8.3%
Royalty income and service income	50.8	85.8	86.9	36.2	30.9	-5.2	-14.4%
Japan	1.3	2.1	8.1	3.8	3.6	-0.2	-6.0%
Overseas	49.5	83.7	78.8	32.3	27.4	-5.0	-15.4%
Total ethical drugs revenue	1,401.5	1,529.1	1,614.5	770.1	825.5	55.4	7.2%
Ratio of overseas ethical drugs revenue	58.0%	61.9%	65.2%	63.2%	67.1%	3.8pt	

\* Revenue amount is classified into countries or regions based on the customer location.

\*\* Effective from FY14, the Company changed the regional classification to ensure consistency with its global organizational structure (previous "North America" was divided into "United States" and "Canada", and "Canada" and previous "Europe" were integrated into "Europe and Canada"). For fair comparison purpose, the amounts reported in the periods of FY12 and FY13 were modified according to the new classification.

\*\*\* Other region includes Middle East, Oceania and Africa.

#### ◆ Major Subsidiaries \*

				(Billion JPY)			
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Takeda Pharmaceuticals U.S.A., Inc.	234.9	213.0	262.4	115.9	160.2	44.3	38.2%
[Millions of US\$]	[2,856]	[2,126]	[2,396]	[1,132]	[1,313]	[181]	[16.0%]
Millennium Pharmaceuticals, Inc.	108.4	144.3	166.0	76.8	89.5	12.7	16.5%
[Millions of US\$]	[1,318]	[1,440]	[1,519]	[749]	[733]	[-16]	[-2.2%]
Wako Pure Chemical Industries, Ltd.	60.3	60.8	68.5	33.1	33.3	0.2	0.6%

\* Revenue amounts for TPC group's intercompany transaction are subtracted.

◆ Ethical Drugs: Global major products' sales

(Billion JPY)

	FY12	FY13*	FY14*	FY14 H1*	FY15 H1*	vs. PrY	increase/ decrease
Velcade	72.9	131.3	152.7	72.8	85.8	13.0	17.8%
Leuprorelin	116.5	126.8	124.0	61.3	62.4	1.0	1.7%
Pantoprazole	78.0	103.7	103.7	50.6	51.9	1.3	2.6%
Lansoprazole	110.2	119.7	102.9	50.1	47.5	-2.6	-5.1%
Candesartan	169.6	157.1	125.7	72.5	44.7	-27.8	-38.3%
Entyvio	-	-	27.8	6.5	36.0	29.4	-
Dexilant	32.7	50.3	62.3	27.2	35.4	8.2	30.1%
Nesina	37.8	40.4	44.3	21.9	24.6	2.8	12.6%
Colcrys	33.6	51.9	58.8	29.8	22.9	-6.9	-23.1%
Uloric	17.7	26.9	33.2	14.1	20.2	6.1	43.2%
Amitiza	22.3	25.7	32.0	13.9	19.2	5.2	37.5%
Adcetris	4.5	13.6	22.9	11.7	14.5	2.8	24.3%
Pioglitazone	122.9	36.8	31.0	18.3	13.9	-4.3	-23.7%
Calcium	15.4	19.7	21.3	10.1	10.3	0.2	2.2%
Tachosil	13.2	17.0	17.9	8.5	9.0	0.5	5.7%
Actovegin	19.6	26.4	20.9	9.9	8.9	-1.0	-10.3%

\*Royalty income and service income are included in and after FY13.

◆ Ethical Drugs: Overseas major products' sales (Regional basis)

(Billion JPY)

	FY12	FY13*	FY14*	FY14 H1*	FY15 H1*	vs. PrY	increase/ decrease
<b>Candesartan</b>							
Overseas sales - total	35.6	31.3	31.1	16.2	13.4	-2.8	-17.2%
<b>Leuprorelin</b>							
United States		15.2	15.9	6.7	8.7	2.0	29.4%
Europe and Canada		35.2	36.4	18.0	17.7	-0.3	-1.8%
Emerging Markets		11.9	14.2	6.9	8.6	1.7	25.2%
Overseas sales - total	50.5	62.3	66.4	31.6	35.0	3.4	10.7%
<b>Lansoprazole</b>							
United States		30.4	28.7	12.0	15.0	3.0	25.0%
Europe and Canada		13.0	11.7	5.8	5.4	-0.3	-5.6%
Emerging Markets		8.7	10.1	4.9	5.3	0.4	7.1%
Overseas sales - total	41.2	52.0	50.4	22.7	25.7	3.0	13.3%
<b>Pantoprazole</b>							
United States		15.4	11.0	3.5	4.8	1.3	37.2%
Europe and Canada		48.4	49.3	24.4	23.7	-0.7	-3.1%
Emerging Markets		39.9	43.4	22.7	23.5	0.8	3.4%
Overseas sales - total	78.0	103.7	103.7	50.6	51.9	1.3	2.6%
<b>Entyvio</b>							
United States	-	-	20.1	4.9	27.2	22.3	-
Europe and Canada	-	-	7.7	1.6	8.3	6.7	-
Emerging Markets	-	-	0.0	0.0	0.5	0.5	-
Overseas sales - total	-	-	27.8	6.5	36.0	29.4	-

\* This chart shows the major overseas products sales classified as "United States", "Europe and Canada" and "Emerging Markets (Latin America, Russia/CIS, Asia and Other regions)" and does not include sales in Japan.

\*\* The sales of Candesartan are shown in sole "Overseas sales - total", because export sales of Candesartan to licensees are recorded under a single route.

\* Royalty income and service income are included in and after FY13.

◆ Ethical Drugs: US major products' sales (in US\$)\*

				(Millions US\$)			
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs PrY	increase/decrease
Velcade	886	953	1,017	505	543	39	7.6%
Dexilant	362	449	488	230	247	17	7.5%
Entyvio	-	-	179	48	223	175	-
Colcryc	408	520	542	291	188	-103	-35.4%
Uloric	212	266	297	135	163	28	20.6%
Amitiza	271	257	291	136	157	21	15.1%
Prevacid (lansoprazole)	295	295	254	113	119	6	5.4%
Brintellix	-	4	124	52	92	40	76.2%
Contrave	-	-	19	-	29	29	-

\*Product sales (royalty income and service income are excluded).

◆ Ethical Drugs: Japan major products' sales

	Launched	Therapeutic Class				(Billion JPY)			
			FY12	FY13	FY14	FY14 H1	FY15 H1	vs PrY	increase/decrease
Blopress * (candesartan)	(99. 6)	Hypertension	134.0	125.8	94.6	56.2	31.3	-25.0	-44.4%
Azilva *	(12. 5)	Hypertension	3.4	25.3	45.4	20.3	28.6	8.3	40.7%
Leuplin (leuprorelin)	(92. 9)	Prostate cancer, breast cancer and endometriosis	66.0	64.5	57.6	29.7	27.4	-2.3	-7.9%
Takepron * (lansoprazole)	(92.12)	Peptic ulcers	69.1	67.6	52.5	27.5	21.9	-5.6	-20.3%
Enbrel	(05. 3)	Rheumatoid arthritis	43.2	45.4	41.2	20.4	21.1	0.7	3.5%
Nesina *	(10. 6)	Diabetes	37.8	38.0	38.4	19.6	19.0	-0.6	-2.9%
Lotriga	(13. 1)	Hyperlipidemia	1.1	5.2	13.2	5.0	10.5	5.5	111.4%
Vectibix	(10. 6)	Colorectal cancer	18.8	19.4	18.3	9.2	9.5	0.3	2.7%
Reminyl	(11. 3)	Alzheimer-type dementia	8.4	12.3	13.9	6.4	7.9	1.5	23.8%
Benet	(02. 5)	Osteoporosis	13.3	11.6	10.4	5.3	5.0	-0.3	-5.0%
Basen	(94. 9)	Diabetes	19.3	16.1	11.2	6.0	4.7	-1.3	-21.9%
Actos (pioglitazone)	(99.12)	Diabetes	19.1	15.5	10.8	5.8	4.6	-1.2	-21.0%
Rozerem	(10. 7)	Insomnia	4.5	6.0	6.6	3.2	3.7	0.5	16.7%
Takecab	(15. 2)	Acid-related Diseases	-	-	3.2	-	2.0	2.0	-
Adcetris	(14. 4)	Malignant Lymphoma	-	-	2.8	1.3	1.6	0.3	20.4%

\* The figures include the amounts of fixed dose combinations.

◆ Consumer Healthcare: Major products' sales

				(Billion JPY)			
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs PrY	increase/decrease
Alinamin tablet	15.7	19.6	20.7	9.9	13.1	3.3	33.0%
Alinamin drink	14.3	15.1	14.9	8.4	8.1	-0.2	-2.9%
Benza	9.7	10.4	9.7	6.0	5.5	-0.4	-7.0%
Biofermin	8.1	8.4	8.1	4.1	4.3	0.2	6.1%
Borraginol	4.3	4.4	4.1	1.9	2.1	0.2	10.7%



#### 4. Consolidated Statement of Financial Position

<Assets>	(Billion JPY)					
	FY12 End	FY13 End	FY14 End	FY15 H1 End	% of Total	vs. FY14 End
Total non-current assets	2,821.2	2,976.6	2,776.1	2,733.6	64.9%	Δ42.5
Property, plant and equipment	546.8	542.3	526.2	517.6	12.3%	-8.6
Acquisition cost	1,109.0	1,167.7	1,177.1	1,186.9		9.9
Accumulated depreciation and impairment losses	-562.2	-625.4	-650.9	-669.3		-18.4
Goodwill	714.0	814.7	821.9	836.3	19.8%	14.4
Intangible assets	1,095.8	1,135.6	939.4	890.0	21.1%	-49.3
Investment property	36.7	32.1	30.2	30.0	0.7%	-0.2
Investments accounted for using the equity method	9.2	10.0	10.4	11.3	0.3%	0.9
Other financial assets	211.8	192.8	241.3	243.3	5.8%	1.9
Investment securities	160.3	141.6	159.7	162.0		2.3
Other non-current assets	27.5	40.8	52.2	50.8	1.2%	-1.4
Prepaid pension costs	23.3	35.8	49.0	48.6		-0.4
Deferred tax assets	179.4	208.4	154.5	154.2	3.7%	-0.3
Total current assets	1,231.4	1,592.5	1,520.1	1,480.2	35.1%	-39.9
Inventories	229.3	254.3	262.4	275.0	6.5%	12.6
Trade and other receivables	375.0	430.6	444.7	471.8	11.2%	27.1
Other financial assets	16.2	185.0	61.3	59.3	1.4%	-2.0
Income tax recoverables	12.0	12.0	22.1	6.6	0.2%	-15.6
Other current assets	49.3	43.5	63.2	58.7	1.4%	-4.5
Cash and cash equivalents	545.6	666.0	652.1	608.3	14.4%	-43.9
Assets held for sale	4.0	1.0	14.2	0.5	0.0%	-13.7
Total Assets	4,052.6	4,569.1	4,296.2	4,213.8	100.0%	-82.4

<Liabilities and equity>

	(Billion JPY)					
	FY12 End	FY13 End	FY14 End	FY15 H1 End	% of Total	vs. FY14 End
Total liabilities	1,714.3	2,028.5	2,090.0	2,031.5	48.2%	-58.5
Total non-current liabilities	1,080.4	1,225.8	1,073.2	1,045.5	24.8%	-27.7
Bonds	471.3	463.3	419.4	419.0	9.9%	-0.4
Long-term loans	111.3	241.3	210.0	210.0	5.0%	-
Other financial liabilities	96.4	110.1	70.1	72.5	1.7%	2.4
Retirement benefit liabilities	66.6	76.5	91.7	84.3	2.0%	-7.4
Provisions	21.8	14.4	47.1	34.8	0.8%	-12.3
Other non-current liabilities	41.1	39.6	78.8	74.9	1.8%	-3.9
Deferred tax liabilities	271.8	280.6	156.1	150.1	3.6%	-6.1
Total current liabilities	633.8	802.8	1,016.8	986.0	23.4%	-30.8
Bonds	-	154.1	70.0	70.0	1.7%	0.0
Short-term loans	1.9	1.3	30.0	30.0	0.7%	-
Trade and other payables	169.9	184.9	170.8	157.7	3.7%	-13.1
Other financial liabilities	38.6	48.8	42.1	36.2	0.9%	-5.9
Income tax payables	129.4	52.3	41.1	67.7	1.6%	26.6
Provisions	100.8	125.3	418.6	423.6	10.1%	5.0
Other current liabilities	193.3	236.0	238.5	200.9	4.8%	-37.6
Liability held-for-sale	-	-	5.8	-	-%	-5.8
Total equity	2,338.3	2,540.6	2,206.2	2,182.3	51.8%	-23.9
Share capital	63.5	63.6	64.0	64.5		0.5
Capital surplus	40.3	39.9	59.6	60.9		1.3
Treasury shares	-0.6	-0.6	-18.2	-35.9		-17.7
Retained earnings	1,927.8	1,901.3	1,601.3	1,593.2		-8.2
Other components of equity	243.1	466.6	430.3	436.9		6.6
Equity attributable to owners of the company	2,274.1	2,470.7	2,137.0	2,119.4		-17.6
Non-controlling interests	64.2	69.9	69.1	62.9		-6.3
Total liabilities and equity	4,052.6	4,569.1	4,296.2	4,213.8	100.0%	-82.4

5. Consolidated Statement of Cash Flows

	(Billion JPY)					
	FY12	FY13	FY14	FY14 H1	FY15 H1	vs. PrY
Net cash from (used in) operating activities	332.6	148.7	182.5	84.7	95.0	10.3
Net cash from (used in) investing activities	-131.1	-154.1	91.3	25.5	-40.9	-66.4
Net cash from (used in) financing activities	-152.2	96.5	-301.0	-106.1	-98.3	7.8
Net increase in cash and cash equivalents	49.3	91.2	-27.1	4.0	-44.2	-48.2
Cash and cash equivalents at beginning of year	454.2	545.6	666.0	666.0	655.2	-10.8
Effect of movements in exchange rates on cash and cash equivalents	42.0	29.3	16.3	11.4	-2.7	-14.1
Cash and cash equivalents at end of year	545.6	666.0	655.2	681.5	608.3	-73.2

## 6. Segment Information

	FY12	FY13	FY14	(Billion JPY)			
				FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Revenue	1,557.0	1,691.7	1,777.8	851.4	904.0	52.7	6.2%
Ethical drugs	1,401.5	1,529.1	1,614.5	770.1	825.5	55.4	7.2%
Japan	588.2	582.1	561.3	283.2	272.0	-11.2	-4.0%
Overseas	813.3	947.0	1,053.2	486.9	553.5	66.6	13.7%
Consumer healthcare	66.9	72.9	73.6	37.7	41.0	3.3	8.8%
Others	88.6	89.8	89.7	43.6	37.5	-6.0	-13.8%
Operating Income	65.0	139.3	-129.3	116.7	110.4	-6.2	-5.4%
Ethical drugs	34.1	112.1	-178.9	80.4	88.4	8.1	10.1%
<% of Ethical drugs sales/revenue>	<2.4%>	<7.3%>	<-11.1%>	<10.4%>	<10.7%>	<0.3pt>	
Consumer healthcare	12.9	16.4	17.2	11.3	13.5	2.2	19.5%
<% of Consumer healthcare sales/revenue>	<19.3%>	<22.5%>	<23.4%>	<30.0%>	<32.9%>	<3.0pt>	
Others	18.0	10.8	32.4	25.0	8.5	-16.5	-66.0%
<% of Others sales/revenue>	<20.3%>	<12.0%>	<36.2%>	<57.5%>	<22.7%>	<-34.8pt>	

## 7. Capital expenditure, depreciation and amortization and impairment losses

	FY12	FY13	FY14	(Billion JPY)			
				FY14 H1	FY15 H1	vs. PrY	increase/ decrease
Capital expenditures (tangible assets)*	72.3	43.9	53.7	26.5	19.5	-7.0	-26.5%
Depreciation (tangible assets)**	55.8	59.3	58.7	28.7	26.0	-2.7	-9.3%
Capital expenditures (intangible assets)	194.4	60.0	47.8	21.9	13.3	-8.6	-39.1%
Amortization (intangible assets)	119.7	127.9	132.9	67.3	63.8	-3.5	-5.2%
Amortization associated with products	112.2	120.1	123.2	62.0	58.5	-3.5	-5.6%
Impairment losses	71.0	27.5	68.4	1.2	4.7	3.5	-
Impairment losses associated with products	62.4	23.1	53.2	1.2	4.5	3.2	-

\* Excluding increase due to acquisition.

\*\* Excluding depreciation for investment assets.

## 8. Number of employees

	FY12 End	FY13 End	FY14 End	FY15 H1 End	% of total	vs. FY14 End
Total ①+②	30,481	31,225	31,328	31,263	100.0%	-65
< Overseas >	<20,956>	<21,671>	<21,716>	<21,961>	<70.2%>	<245>
Ethical drugs	27,947	28,672	28,761	28,905	92.5%	145
Consumer healthcare	450	461	457	474	1.5%	17
Others	2,084	2,092	2,110	1,884	6.0%	-227
Employees working in Takeda Pharmaceutical Company Limited ①	6,544	6,578	6,780	6,792	21.7%	12
Consolidated subsidiaries ②	23,937	24,647	24,548	24,471	78.3%	-77

\* Employees on the full time equivalent basis

## 9. Shareholders

### 【By ownership】

		FY12 End	FY13 End	FY14 End	FY15 H1 End	vs. FY14 End
Financial Institutions	No. of shareholders	311	313	277	272	-5
	No. of shares(1000)	250,440	235,353	235,524	238,761	3,237
	% of shares outstanding	31.71	29.80	29.82	30.21	0.39
Registered Financial Instruments Firms	No. of shareholders	59	67	47	59	12
	No. of shares(1000)	37,273	38,582	41,794	38,784	-3,010
	% of shares outstanding	4.72	4.88	5.29	4.91	-0.38
Other institutions	No. of shareholders	1,772	1,890	1,567	1,509	-58
	No. of shares(1000)	41,596	41,626	41,751	41,088	-664
	% of shares outstanding	5.27	5.27	5.29	5.20	-0.09
Foreign investors	No. of shareholders	861	883	891	871	-20
	No. of shares(1000)	221,281	223,377	255,976	262,531	6,556
	% of shares outstanding	28.02	28.29	32.40	33.23	0.83
Private investors and others	No. of shareholders	275,841	305,206	266,344	258,072	-8,272
	No. of shares(1000)	238,953	250,612	214,742	208,845	-5,897
	% of shares outstanding	30.26	31.74	27.18	26.43	-0.75
Takeda	No. of shares(1000)	123	130,353	138	142	5
	% of shares outstanding	0.02	0.02	0.02	0.02	0.00

### 【By number of shares held each】

		FY12 End	FY13 End	FY14 End	FY15 H1 End	vs. FY14 End
5,000,000~	No. of shareholders	25	21	25	26	1
	No. of shares(1000)	300,172	267,568	311,874	337,558	25,685
	% of shares outstanding	38.01	33.88	39.48	42.72	3.24
1,000,000~ 4,999,999	No. of shareholders	79	91	82	75	-7
	No. of shares(1000)	176,679	203,000	190,704	178,146	-12,558
	% of shares outstanding	22.37	25.71	24.14	22.55	-1.60
100,000~ 999,999	No. of shareholders	288	273	280	274	-6
	No. of shares(1000)	92,399	85,950	88,306	81,795	-6,511
	% of shares outstanding	11.70	10.88	11.18	10.35	-0.83
10,000~ 99,999	No. of shareholders	2,373	2,472	2,126	2,100	-26
	No. of shares(1000)	49,309	50,890	44,904	43,693	-1,211
	% of shares outstanding	6.25	6.45	5.70	5.53	-0.17
1,000~ 9,999	No. of shareholders	60,392	63,080	52,696	50,740	-1,956
	No. of shares(1000)	120,618	126,265	106,438	102,829	-3,610
	% of shares outstanding	15.28	15.99	13.48	13.01	-0.47
100~ 999	No. of shareholders	206,147	232,953	205,140	199,044	-6,096
	No. of shares(1000)	50,234	55,762	47,466	45,906	-1,560
	% of shares outstanding	6.36	7.06	6.01	5.81	-0.20
Less than 99	No. of shareholders	9,541	9,470	8,778	8,525	-253
	No. of shares(1000)	255	247	231	224	-7
	% of shares outstanding	0.03	0.03	0.03	0.03	-0.00
Total	No. of shareholders	278,845	308,360	269,127	260,784	-8,343
	No. of shares(1000)	789,666	789,681	789,924	790,151	228

### 【10 largest shareholders】

Shareholders	No. of shares held (1,000)	FY15 H1 End % of shares outstanding	Change from FY14 End	
			No. of shares increase/decrease (1,000)	Previous ranking
1 Nippon Life Insurance Company	50,760	6.42	-	<1>
2 The Master Trust Bank of Japan, Ltd. (Trust account)	33,678	4.26	2,632	<2>
3 JP Morgan Chase Bank 380055	29,273	3.70	9,932	<4>
4 Japan Trustee Services Bank, Ltd. (Trust account)	27,550	3.49	968	<3>
5 Takeda Science Foundation	17,912	2.27	-	<5>
6 Barclays Securities Japan Limited	15,000	1.90	-	<6>
7 JP Morgan Chase Bank 385147	13,934	1.76	553	<7>
8 State Street Bank West Client-Treaty 505234	12,949	1.64	1,591	<8>
9 The Bank of New York Mellon SA/NV 10	10,739	1.36	1,243	<10>
10 State Street Bank And Trust Company 505223	10,617	1.34	3,108	<19>

## 10. Financial ratios

	FY12	FY13	FY14	FY14 H1	FY15 H1
<b>[Growth rates]</b>					
Revenue (%)		8.6	5.1	2.8	6.2
Operating profit (%)		114.3	-	6.2	-5.4
Net profit (%) *		-28.2	-	-22.0	-11.5
<b>[Profitability ratios]</b>					
Gross profit margin (%)	70.2	71.0	70.7	71.0	71.5
Operating margin (%)	4.2	8.2	-7.3	13.7	12.2
Net margin (%) *	9.5	6.3	-8.2	7.2	6.0
Return on total assets (%) *	3.9	2.5	-3.3	2.7	2.6
Return on equity attributable to owners of the Company (ROE) (%)	6.8	4.5	-6.3	5.0	5.1
<b>[Stability ratios]</b>					
Ratio of equity attributable to owners of the Company to total assets (%)	56.1	54.1	49.7	53.9	50.3
Current ratio (%)	194.3	198.4	149.5	209.7	150.1
Non-current assets to long-term capital (%) *	84.1	80.5	86.5	78.9	86.4
<b>[Efficiency ratios]</b>					
Asset turnover (times)	0.38	0.37	0.41	0.37	0.43
Fixed-asset turnover (times)	0.55	0.57	0.64	0.58	0.66
Notes and accounts receivable turnover (times) **	4.50	4.45	4.40	4.10	4.18
<b>[Other ratios]</b>					
R&D expenses to revenue (%)	20.6	20.2	21.5	18.4	17.9
Equity attributable to owners of the Company per share (JPY)	2,881	3,130	2,719	3,136	2,705
Basic earnings per share (EPS) (JPY) *	188.21	135.10	-185.37	78.07	69.34
Growth Rate of EPS (%)		-28.2	-	-21.7	-11.2
Payout ratio (%)	95.6	133.2	-	115.3	129.8
Dividend on equity attributable to owners of the Company (DOE) (%)	6.5	6.0	6.2	5.7	6.6

\* Ratios are calculated based on amounts attributable to owners of the Company.

\*\* "Notes and accounts receivable turnover" are after adjustment of outstanding balance at each fiscal year end and/or 1st half of fiscal year if the ending day falls on weekend or holiday, and to be paid on the beginning day of the following fiscal term.

### III. Pipeline

#### 1. Development activities

This table primarily shows the indications for which we will actively pursue approval. We are also conducting additional studies of certain assets to examine their potential for use in further indications.

##### ■ US/EU/Jpn

Development in regions where compound is not yet approved. Additional indications/formulations/important label updates in regions where compound is already approved are shown in the table "Additional indications/formulations/important label updates of approved compounds"

Development code <generic name> Brand name (country / region)	Drug Class (administration route)	Indications	Stage	
<glatiramer acetate> Copaxone® (Jpn)	Immunomodulator (injection)	Relapse prevention of multiple sclerosis	Jpn	Approved (Sep '15)
<b>TAK-816</b> *1	Hib vaccine (injection)	Prevention of infectious disease caused by Haemophilus influenzae type b (Hib)	Jpn	Filed (Sep '13)
<b>MLN9708</b> <ixazomib>	Proteasome inhibitor (oral)	Relapsed or refractory multiple myeloma	US	Filed (Jul '15)
			EU	Filed (Jul '15)
			Jpn	P-III
		Previously untreated multiple myeloma	US	P-III
			EU	P-III
			Jpn	P-III
		Maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant	US	P-III
			EU	P-III
			Jpn	P-III
		Maintenance therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant	US	P-III
	EU	P-III		
	Jpn	P-III		
		Relapsed or refractory primary (AL) amyloidosis	US	P-III
			EU	P-III
		Solid tumors	US	P-I
<b>MLN0002</b> <vedolizumab> Entyvio® (US, EU)	Humanized monoclonal antibody against α4β7 integrin (injection)	Ulcerative colitis Crohn's disease	Jpn	P-III
			Jpn	P-III
<b>Lu AA21004</b> <vortioxetine> Brintellix® (US)	Multimodal anti-depressant (oral)	Major depressive disorder	Jpn	P-III
<b>AMG 386</b> <trebananib>	Anti-angiopoietin peptibody (injection)	Ovarian cancer	Jpn	P-III
<b>TVP-1012</b> *2 <rasagiline>	Monoamine oxidase B (MAO-B) inhibitor (oral)	Parkinson's disease	Jpn	P-III
<b>MLN8237</b> <alisertib>	Aurora A kinase inhibitor (oral)	Small cell lung cancer	US	P-II(b)
			EU	P-II(b)
		Non-Hodgkin lymphoma	Jpn	P-I
		Solid tumors	Jpn	P-I
<b>TAK-385</b> <relugolix>	LH-RH antagonist (oral)	Prostate cancer	US	P-II(b)
			EU	P-II(b)
			Jpn	P-I
		Endometriosis	Jpn	P-II(b)
		Uterine fibroids	Jpn	P-II(b)
<b>TAK-228</b> *3 <->	mTORC1/2 inhibitor (oral)	Breast cancer	US	P-II(b)
			EU	P-II(b)
		Renal cancer	US	P-II(b)
		Endometrial cancer	US	P-II(b)
		Solid tumors	-	P-I

\*1 Brand name in GSK territories: Vaxem Hib®

\*2 Brand name in Teva territories: Azilect®

\*3 Formerly known as MLN0128

Development code/product name <generic name>	Drug Class (administration route)	Indications	Stage	
<b>MT203</b> <namilumab>	GM-CSF monoclonal antibody (injection)	Psoriasis	EU	P-II(b)
		Rheumatoid arthritis	EU	P-II(b)
			Jpn	P-II(b)
<b>TAK-272</b> < - >	Direct renin inhibitor (oral)	Early stage diabetic nephropathy	Jpn	P-II(b)
<b>TAK-003</b>	Tetravalent dengue vaccine (injection)	Prevention of dengue fever caused by dengue virus	-	P-II(b)
<b>TAK-214</b>	Norovirus vaccine (injection)	Prevention of acute gastroenteritis (AGE) caused by norovirus	-	P-II(b)
<b>TAK-114</b> < - >	Pro-inflammatory cytokine inhibitor (oral)	Ulcerative colitis	US	P-II(a)
			EU	P-II(a)
			Jpn	P-I
<b>TAK-063</b> < - >	PDE10A inhibitor (oral)	Schizophrenia	US	P-II(a)
<b>TAK-850</b>	Seasonal influenza vaccine (injection)	Prevention of influenza disease caused by influenza virus subtype A and B contained in the vaccine	Jpn	P-II(a)
<b>TAK-659</b> < - >	SYK kinase inhibitor (oral)	Solid tumors, Hematologic malignancies	-	P-I
<b>TAK-233</b> < - >	(oral)	Women's health	-	P-I
<b>TAK-935</b> < - >	CH24H inhibitor (oral)	Epilepsy	-	P-I
<b>TAK-058</b> < - >	5-HT3 receptor antagonist (oral)	Schizophrenia, especially cognitive impairment associated with schizophrenia	-	P-I
<b>TAK-079</b> < - >	Cytolytic monoclonal antibody (injection)	Rheumatoid arthritis, Systemic lupus erythematosus	-	P-I
<b>TAK-020</b> < - >	Bruton's tyrosine kinase inhibitor (oral)	Rheumatoid arthritis	-	P-I
<b>TAK-021</b>	EV71 vaccine (injection)	Prevention of hand, foot and mouth disease caused by enterovirus 71	-	P-I
<b>TAK-924</b> <sup>*4</sup> < - >	NEDD 8 activating enzyme inhibitor (injection)	Advanced malignancies, Acute myeloid leukemia	-	P-I
<b>TAK-117</b> <sup>*5</sup> < - >	PI3K $\alpha$ isoform inhibitor (oral)	Solid tumors, Non-small cell lung cancer	-	P-I
<b>TAK-243</b> <sup>*6</sup> < - >	UAE inhibitor (injection)	Solid tumors	-	P-I
<b>TAK-648</b> < - >	PDE4 inhibitor (oral)	Diabetic nephropathy	-	P-I
<b>TAK-915</b> < - >	PDE2A inhibitor (oral)	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
<b>TAK-653</b> < - >	AMPA receptor potentiator (oral)	Psychiatric disorders, Neurological diseases	-	P-I
<b>TAK-831</b> < - >	D-amino acid oxidase (DAAO) inhibitor (oral)	Cerebellar ataxia, Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
<b>TAK-580</b> <sup>*7</sup> < - >	pan-Raf kinase inhibitor (oral)	Solid tumors	-	P-I

\*4 Formerly known as MLN4924

\*5 Formerly known as MLN1117

\*6 Formerly known as MLN7243

\*7 Formerly known as MLN2480



Development code/ product name <generic name>	Drug Class (administration route)	Indications	Stage	
Lu AA24530 <- ->	Multimodal anti-depressant (oral)	Major depressive disorder, Generalized anxiety disorder	US Jpn	P-I P-I
AMG 403 <fulranumab>	Human monoclonal antibody against human Nerve Growth Factor (NGF) (injection)	Pain	Jpn	P-I

## ■ Additional indications/formulations/important label updates of approved compounds

Development code <generic name> Brand name (country / region)	Drug Class	Indications or formulations	Stage	
<b>TAP-144-SR</b> <leuprorelin acetate> Leuplin® (Jpn) Lupron Depot® (US) Enantone®, etc. (EU)	LH-RH agonist	Prostate cancer, Premenopausal breast cancer (6-month formulation)	Jpn	Approved (Sep '15)
<b>TAK-390MR</b> <dexlansoprazole> Dexilant® (US)	Proton pump inhibitor	Acid-related diseases (orally disintegrating tablet) Acid-related diseases in adolescents	US US EU	Filed (Mar '15) Filed (Sep '15) Filed (Sep '15)
<b>SGN-35</b> <brentuximab vedotin> Adcetris® (EU, Jpn)	CD30 monoclonal antibody-drug conjugate	Post-ASCT Hodgkin lymphoma Relapsed cutaneous T-cell lymphoma Front line Hodgkin lymphoma Front line mature T-cell lymphoma	EU EU Jpn EU Jpn	Filed (Mar '15) P-III P-III P-III P-III
<b>Lu AA21004</b> <vortioxetine> Brintellix® (US)	Multimodal anti-depressant	Addition of clinical data to the product label regarding the effect of vortioxetine on certain aspects of cognitive function in adults with Major Depressive Disorder Generalized anxiety disorder Attention Deficit Hyperactivity Disorder (ADHD) in adult patients	US US US	Filed (May '15) P-III P-II(a)
<b>SYR-322</b> <alogliptin> Nesina® (US, Jpn) Vipidia® (EU)	DPP-4 inhibitor	Type 2 diabetes (fixed-dose combination with metformin)	Jpn	Filed (Sep '15)
<b>AD-4833/TOMM40</b>	Insulin sensitizer/ Biomarker assay	Delay of onset of mild cognitive impairment due to Alzheimer's disease	US EU	P-III P-III
<lubiprostone> Amitiza® (US)	Chloride channel activator	New formulation Pediatric functional constipation	US US	P-III P-III
<febuxostat XR> Uloric® (US)	Non-purine, selective xanthine oxidase inhibitor	Hyperuricemia (extended-release formulation)	US	P-III
<b>TAK-536</b> <azilsartan> Azilva® (Jpn)	Angiotensin II receptor blocker	Hypertension (fixed-dose combination with amlodipine and hydrochlorothiazide)	Jpn	P-III
<b>NE-58095NF</b> <risedronate> Benet® (Jpn)	Bone resorption inhibitor	Osteoporosis (additional formulation; change of the dosage and administration)	Jpn	P-II/III
<b>MLN0002</b> <vedolizumab> Entyvio® (US, EU)	Humanized monoclonal antibody against α4β7 integrin	Ulcerative colitis, Crohn's disease (subcutaneous formulation)	-	P-I

■ **Recent progress in stage** Progress in stage disclosed since release of FY2014 results (May 15<sup>th</sup>, 2015)

Development code <generic name>	Indications	Country/Region	Progress in stage
<b>MLN9708</b> <ixazomib>	Relapsed or refractory multiple myeloma	US	Filed (Jul '15)
<b>TAK-228</b> <->	Renal cancer	US	P-II(b)
<b>TAK-228</b> <->	Endometrial cancer	US	P-II(b)
<b>TAK-648</b> <->	Diabetic nephropathy	-	P-I
<b>TAK-915</b> <->	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
<b>&lt;glatiramer acetate&gt;</b>	Relapse prevention of multiple sclerosis	Jpn	Approved (Sep '15)
<b>TAP-144-SR</b> <leuprorelin acetate>	Prostate cancer, Premenopausal breast cancer (6-month formulation)	Jpn	Approved (Sep '15)
<b>Lu AA21004</b> <vortioxetine>	Addition of clinical data to the product label regarding the effect of vortioxetine on certain aspects of cognitive function in adults with Major Depressive Disorder	US	Filed (May '15)
<b>MLN9708</b> <ixazomib>	Relapsed or refractory multiple myeloma	EU	Filed (Jul '15)
<b>TAK-390MR</b> <dexlansoprazole>	Acid-related diseases in adolescents	US, EU	Filed (Sep '15)
<b>SYR-322</b> <alogliptin>	Type 2 diabetes (fixed-dose combination with metformin)	Jpn	Filed (Sep '15)
<b>MT203</b> <namilumab>	Rheumatoid arthritis	Jpn	P-II(b)
<b>TAK-063</b> <->	Schizophrenia	US	P-II(a)
<b>TAK-850</b>	Prevention of influenza disease caused by influenza virus subtype A and B contained in the vaccine	Jpn	P-II(a)
<b>TAK-653</b> <->	Psychiatric disorders, Neurological diseases	-	P-I
<b>TAK-831</b> <->	Cerebellar ataxia, Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I

Progress in stage disclosed since the announcement of FY2015 Q1 results (July 30<sup>th</sup>, 2015) are listed under the bold dividing line

■ **Discontinued projects** Discontinuation disclosed since release of FY2014 results (May 15<sup>th</sup>, 2015)

Development code <generic name>	Indications (Stage)	Reason
<b>TAK-137</b> <->	Psychiatric disorders, Neurological diseases (P-I)	Pharmacokinetic variability led to decrease in safety margin.
<b>TAK-733</b> <->	Solid tumors (P-I)	Development terminated based on a strategic portfolio decision.
<b>TAK-264<sup>*8</sup></b> <->	Gastric cancer, Pancreatic cancer (US, EU P-II)	Development terminated due to lack of efficacy
<b>TAK-272</b> <->	Hypertension (P-I)	Reconsideration of the development program for TAK-272

\*8 Formerly known as MLN0264

Discontinued projects disclosed since the announcement of FY2015 Q1 results (July 30<sup>th</sup>, 2015) are listed under the bold dividing line

■ **Filings and Approvals in Brazil, China & Russia**

Takeda is steadily progressing its pipeline assets through the filing and approval process on a global scale, including in emerging markets. This table shows filings and approvals in the key emerging markets of Brazil, China & Russia.

Country	Development code/generic name (stage)
<b>Brazil</b>	alogliptin/metformin (Filed Jul '13), alogliptin/pioglitazone (Filed Dec '13), ramelteon <sup>*9</sup> (Filed Mar '14), vedolizumab (Approved May '15)
<b>China</b>	brentuximab vedotin (Filed May '13)
<b>Russia</b>	alogliptin/metformin (Filed Mar '14), brentuximab vedotin (Filed May '14), vedolizumab (Filed Jun '15)

\*9 TAK-375 <ramelteon> MT1/MT2 receptor agonist (oral) for the treatment of insomnia

## ■ Clinical study protocol summaries

All clinical study protocol summaries are disclosed on the English-language web-site (<http://www.takeda.com/c-t/>) and all clinical study protocol information in the Japanese-language is disclosed on the Japanese-language web-site (<http://www.takeda.co.jp/c-t/>).

We anticipate that this disclosure assure transparency of information on the clinical trials for the benefit of healthcare professionals, their patients and other stakeholders, which we believe will contribute to the appropriate use of Takeda's products worldwide.

## 2. Research Activities

### ■ Main joint research activities

#### (1) Joint researches with domestic research organizations and companies

Partner	Research subject	Schedule
Kyoto University	Research collaboration for basic and clinical research project of discovering treatments for obesity and schizophrenia based on CNS control	2011/1-2016/3
Keio University, Niigata University	For the search for and functional analysis of disease-related RNA-binding proteins	2015/3-2018/3
Center for iPS Cell Research Application (CiRA), Kyoto University	To develop clinical applications of iPS cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer	2015/4-2025/3
National Cancer Center of Japan	The partnership to develop basic research to clinical development by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research	2015/4-2018/4

#### (2) Joint research with overseas research organizations and companies

Partner	Country	Research subject	Schedule
Seattle Genetics	US	Research collaboration on Antibody-Drug Conjugate	2009/3-
Sage Bionetworks	US	Research collaboration on discovering effective therapeutic targets for Central Nervous System (CNS) disease	2010/11-2015/6
Florida Hospital, Sanford-Burnham Medical Research Institute	US	Research collaboration to target obesity	2010/12-2016/2
Zinfandel Pharmaceuticals	US	Licensing agreement for Alzheimer's Disease Biomarker TOMM40 for the risk of Alzheimer's disease	2010/12-
BC Cancer Agency	Canada	Research collaboration to explore new drug targets based on gene analysis	2012/8-2015/8
Advinus Therapeutics Limited	India	Discovery collaboration to generate IND-ready compounds for major therapeutic areas, including Inflammation, CNS, GI and Metabolic diseases	2012/10-2015/9
Resolve Therapeutics	US	Option to acquire Fc fusion antibody with nuclease for the treatment of Systemic Lupus Erythematosus (SLE) after completion of Phase 1b	2013/2-
Tri-Institutional Therapeutics Discovery Institute	US	Collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies	2013/10 -2017/6
Trianni, Inc.	US	Agreement for use of Trianni's transgenic mouse platform to identify fully human monoclonal antibodies against disease targets in all therapeutic areas	2014/3-
MacroGenics	US	Collaboration to research and develop product candidates that will be directed against jointly selected pairs of molecular targets and using MacroGenics' Dual-Affinity Re-Targeting (DART®) proprietary platform.	2014/9-
ImmunoGen, Inc.	US	Research collaboration on Antibody-Drug Conjugate	2015/3-
Gencia LLC	US	Collaboration to research and develop a new class of small molecules called Mitochondrial Associated Glucocorticoid Receptors (MAGR), agonists for potential use primarily in hematological and inflammatory diseases	2015/8-

